David Brady compensation by year
Zura Bio Summary Compensation Table · the one fiscal year held| Component | FY2022 |
|---|---|
| Salary | $125,051 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $28,846 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $153,897 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zura Bio Ltd DEF 14A filed May 19, 2023, accession 0001104659-23-062684, and prior-year filings.
How this page was built: the Zura Bio Ltd filed document, accession 0001104659-23-062684. Every figure is read from that document and cited to the page and table it appears in. Filed May 19, 2023.
Zura Bio’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Oliver Levy | Director and Chief Financial Officer | $736,625 |
| David Brady · this page | Head of Business Development | $153,897 |
The full Zura Bio compensation record
free company briefThis page is one person within Zura Bio's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zura Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.